ABION Appoints Professor Park Geunchil as Outside Director... Authority in Lung Cancer Field

Park Geun-chil, newly appointed outside director of ABION (Distinguished Professor HCR, School of Medicine, Sungkyunkwan University)

[Asia Economy Reporter Chunhee Lee] On the 23rd, anticancer drug development company Abion announced that at the extraordinary general meeting of shareholders held the previous day, they newly appointed Professor Park Geunchil of Sungkyunkwan University School of Medicine as an outside director.

Outside director Park Geunchil graduated from Seoul National University College of Medicine and earned a Ph.D. in medicine from the same graduate school. He served as a professor in the Department of Hematology and Oncology at Samsung Medical Center, Sungkyunkwan University School of Medicine, and was also selected as an HCR (Highly Cited Researcher) endowed professor. Additionally, he held positions such as Director of the Cancer Medicine Research Institute and Head of the Lung Cancer Center at Samsung Medical Center, and externally served as an executive director of the International Association for the Study of Lung Cancer (IASLC) and chairman of the Korean Society of Clinical Oncology.

Director Park is recognized as a leading authority in lung cancer, being the first domestic researcher to participate in investigator-initiated international collaborative clinical research. He established the basic guidelines for adjuvant chemotherapy to prevent recurrence after curative resection of lung cancer. From 2020 to 2021, he was ranked among the top 1% of researchers in the field of Clinical Medicine by Clarivate Analytics, a global academic information company.

Since 2013, he has been an essential member of the International Cancer Genome Consortium (ICGC) and successfully led the organization of the 2017 Seoul International Workshop as chairman of the organizing committee. Since 2017, he has actively participated as an operating committee member in the second phase project, ICGC-Accelerating Research in Genomic Oncology (ARGO), collaborating with world-renowned scholars on developing genome-tailored technologies for lung cancer.

An Abion representative stated, “By recruiting Professor Park Geunchil, a world-renowned lung cancer research authority, as an outside director, we expect to further enhance the company’s expertise and gain momentum in research on non-small cell lung cancer treatments.” They added, “Director Park will be responsible for advising on global clinical and business development aspects of Abion’s anticancer drug development going forward.”